Reverse Transcribing DNA Viruses

Industry

  • CPC
  • C12N2730/00
This industry / category may be too specific. Please go to a parent level for more data

Sub Industries

C12N2730/00011Reverse Transcribing DNA Viruses C12N2730/00021Viruses as such C12N2730/00022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2730/00023Virus like particles [VLP] C12N2730/00031Uses of virus other than therapeutic or vaccine C12N2730/00032Use of virus as therapeutic agent, other than vaccine C12N2730/00033Use of viral protein as therapeutic agent other than vaccine C12N2730/00034Use of virus or viral component as vaccine C12N2730/00041Use of virus, viral particle or viral elements as a vector C12N2730/00042virus or viral particle as vehicle C12N2730/00043viral genome or elements thereof as genetic vector C12N2730/00044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2730/00045Special targeting system for viral vectors C12N2730/00051Methods of production or purification of viral material C12N2730/00052relating to complementing cells and packaging systems for producing virus or viral particles C12N2730/00061Methods of inactivation or attenuation C12N2730/00062by genetic engineering C12N2730/00063by chemical treatment C12N2730/00064by serial passage C12N2730/00071Demonstrated in vivo effect C12N2730/00088For redistribution C12N2730/10011Hepadnaviridae C12N2730/10021Viruses as such C12N2730/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2730/10023Virus like particles [VLP] C12N2730/10031Uses of virus other than therapeutic or vaccine C12N2730/10032Use of virus as therapeutic agent, other than vaccine C12N2730/10033Use of viral protein as therapeutic agent other than vaccine C12N2730/10034Use of virus or viral component as vaccine C12N2730/10041Use of virus, viral particle or viral elements as a vector C12N2730/10042virus or viral particle as vehicle C12N2730/10043viral genome or elements thereof as genetic vector C12N2730/10044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2730/10045Special targeting system for viral vectors C12N2730/10051Methods of production or purification of viral material C12N2730/10052relating to complementing cells and packaging systems for producing virus or viral particles C12N2730/10061Methods of inactivation or attenuation C12N2730/10062by genetic engineering C12N2730/10063by chemical treatment C12N2730/10064by serial passage C12N2730/10071Demonstrated in vivo effect C12N2730/10088For redistribution C12N2730/10111Orthohepadnavirus C12N2730/10121Viruses as such C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2730/10123Virus like particles [VLP] C12N2730/10131Uses of virus other than therapeutic or vaccine C12N2730/10132Use of virus as therapeutic agent, other than vaccine C12N2730/10133Use of viral protein as therapeutic agent other than vaccine C12N2730/10134Use of virus or viral component as vaccine C12N2730/10141Use of virus, viral particle or viral elements as a vector C12N2730/10142virus or viral particle as vehicle C12N2730/10143viral genome or elements thereof as genetic vector C12N2730/10144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2730/10145Special targeting system for viral vectors C12N2730/10151Methods of production or purification of viral material C12N2730/10152relating to complementing cells and packaging systems for producing virus or viral particles C12N2730/10161Methods of inactivation or attenuation C12N2730/10162by genetic engineering C12N2730/10163by chemical treatment C12N2730/10164by serial passage C12N2730/10171Demonstrated in vivo effect C12N2730/10188For redistribution